Drugs / TAK-662
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04984889 | Sep 2021 → Mar 2022 | hereditary thrombophilia due to congenital protein C deficiency | Takeda | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-662 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04984889 ↗ |
| Modality | Protein / enzyme biologic | “TAK-662 is Protein C Concentrate, which is a lyophilized, sterile concentrate of human protein C.” NCT04984889 ↗ |
| Route | Intravenous | “Patients received a single intravenous dose (80 IU/kg) of human plasma-derived protein C concentrate.” PMID 41859023 ↗ Mar 2026 |